- KalVista Pharmaceuticals Provides Operational Update and Fiscal Year Financial Results
- KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- KalVista Initiates KONFIDENT-KID Trial for On-demand Treatment of Hereditary Angioedema Attacks with Sebetralstat in Children Aged 2 to 11
- KalVista Submits New Drug Application to FDA for Sebetralstat as First Oral On-demand Treatment for Hereditary Angioedema
- KalVista Pharmaceuticals Presents Data at Eastern Allergy Conference 2024 and the Japanese Dermatological Association 2024
- KalVista Pharmaceuticals Presents Data on Persisting Unmet Needs in Hereditary Angioedema at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2024
- KalVista Pharmaceuticals Announces New England Journal of Medicine Publishes Oral Sebetralstat Phase 3 Data Demonstrating its Potential to Transform the Treatment Landscape for People with Hereditary Angioedema
- KalVista Pharmaceuticals Announces Ten Abstracts Accepted for Presentation at the European Academy of Allergy and Clinical Immunology Congress 2024
- KalVista Pharmaceuticals to Present at Upcoming Investor Conferences
- KalVista Pharmaceuticals Highlights Strategic Plans for Coming Fiscal Year
More ▼
Key statistics
On Tuesday, Kalvista Pharmaceuticals Inc (KALV:NMQ) closed at 15.39, -8.83% below its 52-week high of 16.88, set on Feb 01, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 15.07 |
---|---|
High | 15.50 |
Low | 14.92 |
Bid | 10.50 |
Offer | 16.00 |
Previous close | 15.14 |
Average volume | 455.02k |
---|---|
Shares outstanding | 42.74m |
Free float | 42.22m |
P/E (TTM) | -- |
Market cap | 647.02m USD |
EPS (TTM) | -3.40 USD |
Data delayed at least 15 minutes, as of Jul 23 2024 21:00 BST.
More ▼